tolerability

NOT Open Access | First-in-human clinical trial to assess safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection

Tags:

First-in-human, clinical trial, safety, tolerability, Pharmacokinetics, P218, malaria chemoprotection

Author(s):

Chughlay MF, Rossignol E, Donini C, El Gaaloul M, Lorch U, Coates S, Langdon G, Hammond T, Möhrle J, Chalon S

Reference:

Br J Clin Pharmacol. 2020 Jan 11

This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effect in healthy subjects.

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

Tags:

monitoring, efficacy, tolerability, artemether–lumefantrine, artesunate–amodiaquine, Treatment, plasmodium falciparum, malaria, Lambaréné, Gabon, clinical trial

Author(s):

Bayode R. Adegbite, Jean R. Edoa, Ayola A. Adegnika, et al.

Reference:

Malaria Journal 2019 18:424, 16 December 2019

Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon.

Search form

You are here